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Comment	  on:	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  in	  rheumatoid	  
arthritis	  patients	  in	  clinical	  practice.	  
	  
Sir,	  	  
I	  was	  pleased	  to	  read	  the	  recent	  paper	  on	  the	  short-­‐term	  value	  of	  tocilizumab	  
(TCZ)	  in	  decreasing	  the	  daily	  oral	  prednisone	  dose	  (DOPD)	  in	  rheumatoid	  
arthritis	  (RA)	  patients	  in	  a	  real	  life	  setting	  [1].	  	  The	  proportion	  of	  RA	  patients	  
receiving	  TCZ	  with	  a	  DOPD	  of	  5	  mg	  or	  less	  increased	  from	  32	  %	  at	  baseline	  to	  54	  
%	  after	  24	  weeks	  and	  12	  %	  were	  off	  prednisone	  at	  24	  weeks	  [1].	  However,	  I	  have	  
some	  concerns	  on	  the	  study	  design,	  the	  reporting	  and	  interpretation	  of	  the	  
results.	  
	  
Table	  2	  did	  not	  report	  the	  results	  of	  the	  intention-­‐to-­‐treat	  analysis	  with	  last	  
observation	  carried	  forward,	  since	  patients’	  numbers	  were	  different	  throughout	  
the	  study	  period.	  	  
The	  dropout	  rate	  of	  19	  %	  and	  the	  use	  of	  the	  last	  observation	  carried	  forward	  
could	  alter	  the	  statistical	  analysis	  between	  baseline	  DOPD	  and	  changes	  of	  either	  
DOPD	  or	  DAS28-­‐ESR	  at	  24	  weeks.	  As	  well,	  the	  DOPD	  was	  decreased	  at	  
physicians’	  discretion	  throughout	  the	  study	  period	  while	  the	  DAS28	  had	  already	  
plateaued	  at	  week	  8.	  
	  
I	  wondered	  if	  the	  authors	  considered	  that	  the	  reduction	  of	  DOPD	  during	  the	  
study	  is	  mostly	  due	  to	  physicians’	  preference	  introducing	  an	  important	  bias.	  As	  
physicians	  were	  expecting	  possible	  benefits	  of	  TCZ	  therapy,	  non-­‐responders	  who	  
had	  higher	  baseline	  DOPD	  had	  also	  the	  most	  reduction	  in	  DOPD	  (-­‐	  7	  mg)	  
compared	  with	  moderate	  responders	  who	  had	  the	  least.	  (-­‐	  2	  mg)	  at	  24	  weeks.	  	  
	  
Lastly,	  the	  authors	  did	  not	  mention	  the	  use	  of	  intra-­‐articular	  corticosteroids	  in	  
their	  study	  protocol	  that	  could	  influence	  the	  DOPD.	  	  Of	  interest,	  active	  use	  of	  
intra-­‐articular	  injections	  in	  case	  of	  synovitis	  and	  physicians’	  adherence	  to	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